Bibliography
- Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006;5(12):993-6
- Zheng CJ, Han LY, Yap CW, Therapeutic targets: progress of their exploration and investigation of their characteristics. Pharmacol Rev 2006;58(2):259-79
- Hewitt DJ, Hargreaves RJ, Curtis SP, Challenges in analgesic drug development. Clin Pharmacol Ther 2009;86(4):447-50
- Zheng C, Han L, Yap CW, Progress and problems in the exploration of therapeutic targets. Drug Discov Today 2006;11(9-10):412-20
- Zhu F, Han L, Zheng C, What are next generation innovative therapeutic targets? Clues from genetic, structural, physicochemical, and systems profiles of successful targets. J Pharmacol Exp Ther 2009;330(1):304-15
- Zhu F, Han B, Kumar P, Update of TTD: Therapeutic Target Database. Nucleic Acids Res 2010;38(Database issue):D787-91
- Wishart DS, Knox C, Guo AC, DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008;36(Database issue):D901-6
- Gao Z, Li H, Zhang H, PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics 2008;9:104
- Therapeutic target database. Available from: http://bidd.nus.edu.sg/group/cjttd/TTD.asp
- Yildirim MA, Goh KI, Cusick ME, Drug-target network. Nat Biotechnol 2007;25(10):1119-26
- Wishart DS, Knox C, Guo AC, DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006;34(Database issue):D668-72
- Lindsay MA. Target discovery. Nat Rev Drug Discov 2003;2(10):831-8
- Drugs@FDA. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
- Altschul SF, Madden TL, Schaffer AA, Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997;25(17):3389-402
- Willett P, Barnard JM, Downs GM. Chemical Similarity Searching. J Chem Inf Comput Sci 1998;38(6):983-96
- Hull RD, Fluder EM, Singh SB, Chemical similarity searches using latent semantic structural indexing (LaSSI) and comparison to TOPOSIM. J Med Chem 2001;44(8):1185-91
- Hert J, Keiser MJ, Irwin JJ, Quantifying the relationships among drug classes. J Chem Inf Model 2008;48(4):755-65
- Hoang B, Frost P, Shi Y, Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 2010;116(22):4560-8
- Santiskulvong C, Konecny GE, Fekete M, Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res 2011;17(8):2373-84
- Brachmann S, Fritsch C, Maira SM, PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. Curr Opin Cell Biol 2009;21(2):194-8
- Chresta CM, Davies BR, Hickson I, AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010;70(1):288-98
- Anand K, Ziebuhr J, Wadhwani P, Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003;300(5626):1763-7
- BLAST: Basic Local Alignment Search Tool. Available from: http://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD = Web&PAGE_TYPE = BlastHome
- Gerstein M. Measurement of the effectiveness of transitive sequence comparison, through a third ‘intermediate’ sequence. Bioinformatics 1998;14(8):707-14
- Steinkuhler C, Biasiol G, Brunetti M, Product inhibition of the hepatitis C virus NS3 protease. Biochemistry 1998;37(25):8899-905
- Chambers TJ, Weir RC, Grakoui A, Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein. Proc Natl Acad Sci USA 1990;87(22):8898-902
- Geitmann M, Dahl G, Danielson UH. Mechanistic and kinetic characterization of hepatitis C virus NS3 protein interactions with NS4A and protease inhibitors. J Mol Recognit 2011;24(1):60-70
- Zhu F, Zheng CJ, Han LY, Trends in the exploration of anticancer targets and strategies in enhancing the efficacy of drug targeting. Curr Mol Pharmacol 2008;1(3):213-32
- Gill AL, Verdonk M, Boyle RG, A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem 2007;7(14):1408-22
- Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007;6(10):834-48
- Bauman JE, Eaton KD, Martins RG. Antagonism of platelet-derived growth factor receptor in non small cell lung cancer: rationale and investigations. Clin Cancer Res 2007;13(15 Pt 2):s4632-6
- Liao YP, Schaue D, McBride WH. Modification of the tumor microenvironment to enhance immunity. Front Biosci 2007;12:3576-600
- Milosevic M, Fyles A, Hedley D, The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol 2004;14(3):249-58
- Milosevic M, Fyles A, Hedley D, Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res 2001;61(17):6400-5
- Heldin CH, Rubin K, Pietras K, High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004;4(10):806-13
- Orth AP, Batalov S, Perrone M, The promise of genomics to identify novel therapeutic targets. Expert Opin Ther Targets 2004;8(6):587-96
- Cheng AC, Coleman RG, Smyth KT, Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol 2007;25(1):71-5
- Han LY, Zheng CJ, Xie B, Support vector machines approach for predicting druggable proteins: recent progress in its exploration and investigation of its usefulness. Drug Discov Today 2007;12(7-8):304-13
- Yao L, Rzhetsky A. Quantitative systems-level determinants of human genes targeted by successful drugs. Genome Res 2008;18(2):206-13
- Hajduk PJ, Huth JR, Tse C. Predicting protein druggability. Drug Discov Today 2005;10(23-24):1675-82
- Hughes B. 2008 FDA drug approvals. Nat Rev Drug Discov 2009;8(2):93-6
- Payne DJ, Gwynn MN, Holmes DJ, Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007;6(1):29-40
- Canfield ML, Walker WR, Brown LG. Contingency interaction analysis in psychotherapy. J Consult Clin Psychol 1991;59(1):58-66
- Edwards A. Large-scale structural biology of the human proteome. Annu Rev Biochem 2009;78:541-68
- Kramer R, Cohen D. Functional genomics to new drug targets. Nat Rev Drug Discov 2004;3(11):965-72
- Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008;4(11):682-90
- Lee GM, Craik CS. Trapping moving targets with small molecules. Science 2009;324(5924):213-15
- Li H, Yap CW, Ung CY, Machine learning approaches for predicting compounds that interact with therapeutic and ADMET related proteins. J Pharm Sci 2007;96(11):2838-60
- Ilag LL, Ng JH, Beste G, Emerging high-throughput drug target validation technologies. Drug Discov Today 2002;7(18 Suppl):S136-42
- Jackson PD, Harrington JJ. High-throughput target discovery using cell-based genetics. Drug Discov Today 2005;10(1):53-60
- Lindsay MA. Finding new drug targets in the 21st century. Drug Discov Today 2005;10(23-24):1683-7
- Ma XH, Shi Z, Tan C, In-silico approaches to multi-target drug discovery : computer aided multi-target drug design, multi-target virtual screening. Pharm Res 2010;27(5):739-49
- Stegmeier F, Warmuth M, Sellers WR, Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin Pharmacol Ther 2010;87(5):543-52